Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Volume Increase - Here's What Happened

Key Points

• Bavarian Nordic shares experienced a significant increase in trading volume, rising 32% to 10,452 shares on a recent Wednesday.
• The company reported quarterly earnings of $0.13 per share and revenue of $189.89 million, with a net margin of 21.11%.
• Bavarian Nordic specializes in life-saving vaccines, including those for smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) shares saw an uptick in trading volume on Wednesday . 10,452 shares were traded during mid-day trading, an increase of 32% from the previous session's volume of 7,905 shares.The stock last traded at $12.25 and had previously closed at $12.30.

Bavarian Nordic Price Performance

The company has a market cap of $2.89 billion, a price-to-earnings ratio of 15.28 and a beta of 1.36. The business's fifty day moving average price is $9.66 and its 200 day moving average price is $8.56.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $189.89 million for the quarter. Bavarian Nordic had a net margin of 21.11% and a return on equity of 11.89%. As a group, equities research analysts anticipate that Bavarian Nordic will post 0.67 EPS for the current year.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.